The mission of LZE GmbH is to translate technologies from research into products and, as a fabless semiconductor company, to bring high‑performance integrated circuits and semiconductor solutions to market. This also applies to the unique FH3DXX family of 3D magnetic field sensors, which is based on the innovative HallinOne® technology developed by Fraunhofer IIS and has already been successfully established in the market. To further expand the HallinOne® sensor family, LZE GmbH is strengthenin...

Jeito Capital (“Jeito”), a leading global independent private equity fund dedicated to Biopharma, is leading an oversubscribed $75 million (€ 65 million2) Series C financing round in Adcendo ApS (“Adcendo”), a biopharma company focused on the development of first-and best-in-class antibody-drug conjugates (ADCs) for the treatment of cancers with high unmet medical need. The investment comes from Jeito Capital’s second fund, which closed on March 31, 2026 with $1.23 billion in committed investor...

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today an invitation for U.S. based organizations to apply for a grant to create training content for healthcare providers to deliver investigational COMP360 psilocybin treatment, if approved. Many high-quality training organizations already exist and have trained thousands of HCPs in core and psilocybin-specific psychedelic care. This gra...

Forensic casework laboratories will now have access to NimaGen’s IDseek® massively parallel sequencing (MPS) kit portfolio through Promega Corporation, following a distribution agreement announced today between the two companies. The IDseek® line is powered by NimaGen’s patented Reverse Complement PCR (RC-PCR) technology to deliver the sensitivity and specificity required for challenging casework samples. These sequencing kits extend the existing Promega portfolio of sample preparation and capi...

EIG, a leading institutional investor in the global energy and infrastructure sectors, today announced the initial closing of EIG Geothermal Catalyst Partners (the “Fund”), a dedicated investment vehicle focused on making investments to support the development of next-generation geothermal projects in the United States. The Fund is designed primarily to provide mid-stage development capital to help advance geothermal projects through key technical and commercial milestones. By supporting proj...

DWK Life Sciences, a global leader in precision glassware and primary packaging solutions for the life sciences industry, is shaping its next chapter: Armin Reiche (64), who has led the company as Managing Director for approximately 25 years, is handing over to Michael Werth effective April 13, 2026. Werth, as the new Group CEO, brings extensive international leadership experience in technology and production-related businesses. Reiche will continue supporting the company as a member of the Adv...

ExaGrid®, the world’s largest independent backup storage vendor providing Tiered Backup Storage with the most comprehensive security and AI-Powered Retention Time-Lock for Ransomware Recovery, today announced that it had a record quarter of bookings and revenue in the first quarter ending March 31, 2026, with double-digit revenue growth over Q1 of 2025. In addition, ExaGrid remained P&L, EBITDA, and free cash flow positive for the 21st consecutive quarter. The company is 100% debt-free, d...

KnowBe4, the world-renowned platform that comprehensively addresses human and agentic AI risk management, today announced the launch of Agent Risk Manager, the industry’s first defense system designed to secure, monitor, and govern the behavior of autonomous AI agents. KnowBe4 Agent Risk Manager arrives as a cornerstone of the KnowBe4 HRM+ platform, fundamentally changing how organizations quantify and mitigate risks of the human and AI workforce. A new security gap has emerged as workflows s...

Samsung Bioepis Co., Ltd. announced today the initiation of Phase 1 clinical trial for SBE303. SBE303 is Samsung Bioepis’s first novel antibody-drug conjugate (ADC) candidate engineered to bind to Nectin-4, an adhesion protein that is specifically expressed in tumor cells, including urothelial cancer, lung cancer, and breast cancer.1 The Phase 1 clinical trial for SBE303 is an open‑label, multi-center, first‑in‑human trial to evaluate the safety, tolerability and efficacy of SBE303 in participa...

Klarna, the global digital bank and flexible payments provider, today announced a new partnership with Aven Hospitality. The agreement brings Klarna’s flexible payment options to the 10,000 hotels connected to Aven Hospitality’s Booking Engine, offering travelers more choice and their favorite payment method. Today, nearly 7 in 10 travelers pay for their trips with a credit card, racking up interest before they've even packed a bag. Hotel stays are no exception. Whether it's a family planning...